JP2009527501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527501A5 JP2009527501A5 JP2008555537A JP2008555537A JP2009527501A5 JP 2009527501 A5 JP2009527501 A5 JP 2009527501A5 JP 2008555537 A JP2008555537 A JP 2008555537A JP 2008555537 A JP2008555537 A JP 2008555537A JP 2009527501 A5 JP2009527501 A5 JP 2009527501A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- alkyl group
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical class *C#N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 230000032258 transport Effects 0.000 claims 3
- 101000703517 Dictyostelium discoideum Sphingosine-1-phosphate lyase Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- -1 hydroxyethyl group Chemical group 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006178 methyl benzyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003009 phosphonic acids Chemical class 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77530906P | 2006-02-21 | 2006-02-21 | |
| PCT/US2007/062513 WO2007098474A1 (en) | 2006-02-21 | 2007-02-21 | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009527501A JP2009527501A (ja) | 2009-07-30 |
| JP2009527501A5 true JP2009527501A5 (enExample) | 2010-04-08 |
Family
ID=38180400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555537A Pending JP2009527501A (ja) | 2006-02-21 | 2007-02-21 | Ｓ１ｐ受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090105315A1 (enExample) |
| EP (1) | EP1991535A1 (enExample) |
| JP (1) | JP2009527501A (enExample) |
| KR (1) | KR20080096780A (enExample) |
| CN (1) | CN101384566A (enExample) |
| AU (1) | AU2007217006A1 (enExample) |
| BR (1) | BRPI0707957A2 (enExample) |
| CA (1) | CA2641661A1 (enExample) |
| IL (1) | IL193042A0 (enExample) |
| RU (1) | RU2008137553A (enExample) |
| WO (1) | WO2007098474A1 (enExample) |
| ZA (1) | ZA200806392B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522977A (ja) | 2004-12-06 | 2008-07-03 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−リン酸のアリールアミドアナログ |
| CA2612661A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| EP1986623A2 (en) * | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| WO2007092638A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| MY149853A (en) | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| CL2007002594A1 (es) | 2006-09-08 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . |
| WO2008064337A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| EP2097397A1 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| EP2099741A2 (en) * | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| UY30829A1 (es) * | 2006-12-21 | 2008-07-31 | Abbott Lab | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato |
| RU2009128063A (ru) | 2006-12-21 | 2011-01-27 | Эбботт Лэборетриз (Us) | Способ получения и выделения отдельных стереоизомеров 1-амино, 3-замещенных фенилциклопентанекарбоксилатов |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| CA2700917A1 (en) | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| WO2009060278A1 (en) * | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
| EP2262782B1 (en) | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| CA2767585C (en) | 2009-07-16 | 2017-09-26 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| EP2542554B1 (en) | 2010-03-03 | 2015-11-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| BR112013013644A2 (pt) * | 2010-12-03 | 2016-09-06 | Allergan Inc | derivados de oxadiazol como moduladores dos receptores de esfingosina 1-fosfato (s1p) |
| MX350009B (es) | 2011-01-19 | 2017-08-23 | Idorsia Pharmaceuticals Ltd | Derivados de 2-metoxi-piridin-4-ilo. |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| KR102220848B1 (ko) | 2015-05-20 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형 |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
| EP3801459B1 (en) | 2018-06-06 | 2024-08-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252741A1 (en) * | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| US7754703B2 (en) * | 2005-02-14 | 2010-07-13 | University Of Virginia Patent Foundation | Cycloalkane-containing sphingosine 1-phosphate agonists |
-
2007
- 2007-02-21 CN CNA2007800058918A patent/CN101384566A/zh active Pending
- 2007-02-21 AU AU2007217006A patent/AU2007217006A1/en not_active Abandoned
- 2007-02-21 BR BRPI0707957-5A patent/BRPI0707957A2/pt not_active IP Right Cessation
- 2007-02-21 RU RU2008137553/04A patent/RU2008137553A/ru not_active Application Discontinuation
- 2007-02-21 WO PCT/US2007/062513 patent/WO2007098474A1/en not_active Ceased
- 2007-02-21 JP JP2008555537A patent/JP2009527501A/ja active Pending
- 2007-02-21 CA CA002641661A patent/CA2641661A1/en not_active Abandoned
- 2007-02-21 KR KR1020087020312A patent/KR20080096780A/ko not_active Withdrawn
- 2007-02-21 EP EP07757284A patent/EP1991535A1/en not_active Withdrawn
-
2008
- 2008-07-23 ZA ZA200806392A patent/ZA200806392B/xx unknown
- 2008-07-24 IL IL193042A patent/IL193042A0/en unknown
- 2008-08-21 US US12/195,606 patent/US20090105315A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009527501A5 (enExample) | ||
| ES2673160T5 (es) | Moduladores selectivos del receptor de la esfingosina 1 fosfato y métodos de síntesis quiral | |
| AU2011281134B2 (en) | Agonists of GPR40 | |
| KR20120069662A (ko) | 피리딘-4-일 유도체 | |
| JP2007512283A5 (enExample) | ||
| KR20090051774A (ko) | 페닐 유도체 및 면역조절제로서 이들의 용도 | |
| KR102212975B1 (ko) | 피리딘-４-일 유도체 | |
| PT2280696E (pt) | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios com ele relacionados | |
| IL287159B1 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| JP2013526494A5 (enExample) | ||
| ES2525298T3 (es) | Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares | |
| JP2013521301A5 (enExample) | ||
| KR20100125380A (ko) | 신규한 아미노메틸 벤젠 유도체 | |
| EP2619190B1 (en) | Substituted oxadiazole compounds and their use as s1p1 agonists | |
| JP2020509005A (ja) | Ｎ−置換イミダゾールカルボン酸エステル系化合物とその調製方法及び用途 | |
| CN103097367A (zh) | 苯丙酸化合物、其制备方法及其医药用途 | |
| DK2697219T3 (en) | NEW PIPERIDINYLMONOCARBOXYLSYRER AS S1P1 receptor agonists | |
| JP2006508116A5 (enExample) | ||
| KR20140003379A (ko) | 스핑고신 1-포스페이트(ｓ１ｐ) 수용체들에 대한 리간드들로서의 5-(바이페닐-4-일)-3-페닐-1,2,4-옥사디아졸릴 유도체들 | |
| HUE031676T2 (en) | An effective medicine for neuropathic pain | |
| JP2025510512A (ja) | Ｌｐａ受容体活性と関連する状態の処置のための化合物および組成物 | |
| KR20140014128A (ko) | 2-메톡시-피리딘-4-일 유도체 | |
| KR20120122705A (ko) | 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 | |
| KR20240047401A (ko) | 중수소화 화합물 | |
| KR20130133803A (ko) | 스핑고신 1-포스페이트 (s1p) 수용체 조절제로서의 신규한 옥사디아졸 유도체 |